Description
Latin name
AMIGRENIN
Release form
Tablets, film-coated white or white with a creamy gray tint, round, biconvex in cross section, one or two layers are visible, the inner layer is white or white with a yellowish tint.
Packing
6 pcs – blister packagings (1) – packs of cardboard.
Pharmacological action
Antimigraine drug. A specific selective agonist of serotonin 5HT1B-1D receptors (5-hydroxytryptamine-1-like) located primarily in the smooth muscles of the walls of the blood vessels of the brain.
Stimulation of 5HT1 receptors leads to selective narrowing of blood vessels in the carotid artery system and a decrease in neurogenic inflammation, without significantly affecting cerebral blood flow. In addition, it has been experimentally established that sumatriptan inhibits trigeminal nerve activity.
It is believed that these effects help to reduce the severity of pain in migraines. The clinical effect is observed 30 minutes after oral administration of the drug.
Pharmacokinetics
Absorption
When ingested, sumatriptan is rapidly absorbed from the digestive tract, after 45 min, its plasma concentration reaches 70% of Cmax. Absolute bioavailability when administered through presystemic metabolism and incomplete absorption is an average of 14%.
Distribution of
Plasma protein binding is 14-21%.
Metabolism
Biotransformed with the formation of metabolites, the main of which is the indole-acetic analog of sumatriptan.
Excretion of
T1 / 2 is 2 hours. The main metabolite of sumatriptan is excreted mainly in the urine as a free acid or glucuronide conjugate.
Indications
Relief of migraine attacks and Horton’s syndrome (histamine cephalgia).
Contraindications
– hemiplegic, basilar and ophthalmoplegic forms of migraine
– coronary heart disease (including angina pectoris)
– peripheral arterial occlusion disease
– uncontrolled arterial hypertension
– stroke or transient cerebrovascular accident (including history)
– severe liver dysfunction
– concomitant use of drugs containing its ergot or taking MAO inhibitors and the period up to 14 days after they are canceled
– pregnancy
– lactation (breastfeeding)
– age of patients under 18 years and over 65
– increased feel nost to the drug.
Use during pregnancy and lactation
The drug is contraindicated for use during pregnancy and during lactation (breastfeeding).
Composition
1 tab. contains:
Active substances:
sumatriptan succinate 140 mg, which corresponds to the content of sumatriptan 100 mg
Excipients:
microcrystalline cellulose – 32 mg,
lactose (milk sugar) – 123.7 mg,
potato starch starch sodium carbohydrate (11.5 mg) 11.5 mg – 9.6 mg,
magnesium stearate – 3.2 mg.
Shell composition:
hypromellose (hydroxypropylmethyl cellulose) – 4.18 mg,
povidone (polyvinylpyrrolidone) – 2.8 mg,
macrogol 4000 (polyethylene glycol 4000) – 1.02 mg,
talcum – 1.12 mg, srdlkg1 titanium dioxide.
Dosage and Administration
Amigrenin is not intended for prophylactic use.
Adults are prescribed a single dose of 50 mg, in some cases 100 mg. The maximum daily dose is 300 mg.
If the symptoms of migraine do not disappear and do not decrease after taking the first dose of Amigrenin, then the drug should not be prescribed again to stop the ongoing attack.
If symptoms have decreased or disappeared, and then resumed, you can take a second dose over the next 24 hours. The interval between doses should be at least 2 hours.
Side effects of
From the cardiovascular system: hyperemia of the skin and mucous membranes, arterial hypotension, tachycardia, palpitations, angina attack, transient increase in blood pressure, transient ECG changes of the ischemic type, bradycardia in isolated cases – manifestations of Raynaud’s syndrome.
From the side of the central nervous system: dizziness, weakness, drowsiness, fatigue, visual impairment (diplopia, scotoma, decreased visual acuity).
From the digestive system: discomfort in the abdomen, dysphagia, nausea, vomiting rarely – ischemic colitis, increased activity of liver enzymes.
Allergic reactions: rash, itching, erythema, urticaria, anaphylaxis.
Others: tingling, heat, heaviness, pressure or contraction in various parts of the body, myalgia are possible.
overdose
Treatment: In case of overdose, the patient should be observed for 10 hours, carrying out symptomatic therapy as needed.
Storage conditions
List B. The drug should be stored in a dry, dark place.
Expiration
2 Year
Deystvuyuschee substances
sumatriptan
Pharmacy terms
Prescription
Dosage Form
Dosage Form
tablets
